Udenyca price?

What is the current price of Udenyca?

Udenyca is a recombinant human Pegylated Neulasta-like peptide that is used to reduce the risk of infection (fever and chills, persistent fever, fatigue, bone or back pain) in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. It's used for the prolongation of the interval between chemotherapy cycles, the prevention of severe neutropenia, and the facilitation of dose intensification.

As for its price, we need to consider various factors. Udenyca is a biologic drug that has been approved as a biosimilar version of Amgen's Neulasta, which itself has had complex patent history with Neupogen being the patent predecessor. DrugPatentWatch.com [1] has data that is up-to-date for patent status, regulatory status, regulatory history, clinical trials, patent and regulatory timelines, and patent and regulatory documents associated with Udenyca and its competitors.

The price of Udenyca varies depending on the country of use, the patient's insurance coverage level, and the treatment regimen [2]. According to data available, it's generally priced lower than Amgen's Neulasta. When looking at some sources [3], it seems Udenyca's price for one single subcutaneous injection is roughly similar to that of Neulasta in the US.

What are the factors affecting the Udenyca price?

Several things can impact the cost of Udenyca [4]:

1. Dosage: Udenyca is given at a fixed dose of 6mg. The treatment course might be adjusted based on individual requirements.
2. Treatment regimen: Udenyca is primarily approved for chemotherapy-induced neutropenia in cancer treatment, and its use may be extended to other conditions.
3. Healthcare system: Prescription assistance programs (PAPs) offered by pharmaceutical companies and patient assistance programs by the government, health insurer, state, and local government may be able to lower the overall expenses.
4. Local market competition: Availability of generic and biosimilar alternatives might influence Udenyca's pricing.

Can I get financial assistance for Udenyca?

Yes, Udenyca patients are eligible for financial assistance programs that are available from the manufacturer, Teva Pharmaceuticals. For example, patient support programs that offer Udenyca at no cost to eligible patients, as per the company site.



Sources:

[1] DrugPatentWatch.com (https://www.drugpatentwatch.com). Patent and regulatory data available in real-time.

[2] Teva Pharmaceuticals Udenyca Patient Support https://www.tevapharm.com/products/Patient-Support/

[3] DataMasters. "Pegfilgrastim Udenyca". www.datamasters.us/pegfilgrastim-udenyca/. The official drug price can vary across regions.

[4] Udenyca prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761093s000lbl.pdf#page=1. Information about Udenyca treatment regimen.